George Demetri - Merrimack Pharmaceuticals Director
| MACK Stock | USD 14.71 0.02 0.14% |
Director
Dr. George Demetri, M.D., serves as Director of the Company. has served as a member of our board of directors since November 2017. Since 1986, Dr. Demetri has served as a Professor of Medicine at Harvard Medical School and as a PhysicianScientist Faculty Member at the DanaFarber Cancer Institute. Dr. Demetri leads a multidisciplinary team at the DanaFarberHarvard Cancer Center focused on developing novel therapies for solid tumors, with an emphasis on sarcomas. Dr. Demetris research and clinical interests have centered on mechanismbased drug development for solid tumors, and he is a worldrenowned expert in the clinical translation of innovative treatment strategies for cancer. Dr. Demetri has contributed to the development of numerous approved therapies, including Gleevec, Sutent, Stivarga, Zelboraf and Votrient, as well as other new targeted therapies in development. Dr. Demetri also currently serves on the board of directors and scientific advisory board of Blueprint Medicines Corporation since 2017.
| Age | 60 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Address | One Broadway, Cambridge, MA, United States, 02142 |
| Phone | 617 720 8606 |
| Web | https://www.merrimack.com |
Merrimack Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0697) % which means that it has lost $0.0697 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0622) %, meaning that it created substantial loss on money invested by shareholders. Merrimack Pharmaceuticals' management efficiency ratios could be used to measure how well Merrimack Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.06. Return On Capital Employed is expected to rise to -0.11 this year. Change To Liabilities is expected to rise to about 25.5 K this year, although the value of Total Current Liabilities will most likely fall to about 418.9 K.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jacqualyn Fouse | Agios Pharm | 56 | |
| Adrian Senderowicz | Puma Biotechnology | 54 | |
| Robert Essner | Amicus Therapeutics | 70 | |
| Michael Raab | Amicus Therapeutics | 53 | |
| Gerald McMahon | Celldex Therapeutics | 62 | |
| Sol Barer | Amicus Therapeutics | 68 | |
| Michael Miller | Puma Biotechnology | 61 | |
| Maykin Ho | Agios Pharm | 65 | |
| Marc TessierLavigne | Agios Pharm | 55 | |
| Richard Broek | Celldex Therapeutics | 48 | |
| Herbert Conrad | Celldex Therapeutics | 85 | |
| Lynn Bleil | Amicus Therapeutics | 54 | |
| Harry Penner | Celldex Therapeutics | 72 | |
| Douglas Cole | Agios Pharm | 54 | |
| Frank Zavrl | Puma Biotechnology | 52 | |
| Mariann Ohanesian | Puma Biotechnology | N/A | |
| Robert Nelsen | Agios Pharm | 51 | |
| David Scadden | Agios Pharm | 65 | |
| George Elston | Celldex Therapeutics | 49 | |
| Karen Shoos | Celldex Therapeutics | 64 | |
| Lewis Cantley | Agios Pharm | 75 | |
Management Performance
| Return On Equity | -0.0622 | ||||
| Return On Asset | -0.0697 |
Merrimack Pharmaceuticals Leadership Team
Elected by the shareholders, the Merrimack Pharmaceuticals' board of directors comprises two types of representatives: Merrimack Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merrimack. The board's role is to monitor Merrimack Pharmaceuticals' management team and ensure that shareholders' interests are well served. Merrimack Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merrimack Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| George Demetri, Director | ||
| Gary Crocker, Independent Chairman of the Board | ||
| Birgit Schoeberl, Head of Discovery | ||
| Richard Peters, President CEO, Principal Financial Officer, Director | ||
| Ulrik Nielsen, Chief Scientific Officer and Sr. VP of Research | ||
| John Mendelsohn, Director | ||
| Ellen Forest, Head of Human Resources | ||
| Yasir AlWakeel, CFO and Head - Corporate Development | ||
| Daryl Drummond, Head of Research | ||
| ScD Sinskey, CoFounder Advisor | ||
| Edward Stewart, Sr. VP of Bus. Devel. and President of Merrimack Healthcare Solutions | ||
| William Sullivan, Head of Fin. and Accounting and Treasurer | ||
| Timothy Surgenor, Secretary | ||
| John Dineen, Director | ||
| Peter Laivins, Head of Devel. | ||
| Gary MBA, Treasurer and Presidentident | ||
| Geoffrey CFA, Director Communications | ||
| Robert Mulroy, CEO and President Executive Director and Member of Executive Committee | ||
| Fazal Khan, VP Manufacturing | ||
| Vivian Lee, Director | ||
| James Quigley, Director | ||
| John Green, Chief Accounting Officer, Controller | ||
| Jean Franchi, CFO,Principal Financial Officer, Principal Accounting Officer, Treasurer | ||
| William Mcclements, Head of Corporate Operations | ||
| Russell Ray, Director | ||
| Michael Porter, Independent Director | ||
| MBA MBA, Treasurer and President | ||
| Geoffrey Grande, IR Contact Officer | ||
| Sergio Santillana, Chief Medical Officer | ||
| Josh Rappaport, IR Contact Officer |
Merrimack Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merrimack Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0622 | ||||
| Return On Asset | -0.0697 | ||||
| Current Valuation | 194.95 M | ||||
| Shares Outstanding | 14.53 M | ||||
| Shares Owned By Insiders | 1.21 % | ||||
| Shares Owned By Institutions | 66.59 % | ||||
| Number Of Shares Shorted | 722.75 K | ||||
| Price To Earning | 65.70 X | ||||
| Price To Book | 11.38 X | ||||
| Gross Profit | (9.1 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merrimack Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Merrimack Stock please use our How to buy in Merrimack Stock guide.Note that the Merrimack Pharmaceuticals information on this page should be used as a complementary analysis to other Merrimack Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Merrimack Stock analysis
When running Merrimack Pharmaceuticals' price analysis, check to measure Merrimack Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merrimack Pharmaceuticals is operating at the current time. Most of Merrimack Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Merrimack Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merrimack Pharmaceuticals' price. Additionally, you may evaluate how the addition of Merrimack Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Merrimack Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merrimack Pharmaceuticals. If investors know Merrimack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merrimack Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.08) | Return On Assets (0.07) | Return On Equity (0.06) |
The market value of Merrimack Pharmaceuticals is measured differently than its book value, which is the value of Merrimack that is recorded on the company's balance sheet. Investors also form their own opinion of Merrimack Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Merrimack Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merrimack Pharmaceuticals' market value can be influenced by many factors that don't directly affect Merrimack Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merrimack Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Merrimack Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merrimack Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.